GlobalData on MSN3d
EMA gives OMPD to Actuate’s pancreatic cancer therapy
Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...
Actuate Therapeutics announces EMA granted OMPD to elraglusib
Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...
AFP2d
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare ...
Stockhead on MSN4d
Health Kick Podcast: Neurizon gears up for big year in tackling ALS
Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.
The Australian23d
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
An OMPD provides a robust framework of benefits, including reduced regulatory fees, free protocol assistance, and market exclusivity for 10 years in the EU upon product approval. During this ...
Hosted on MSN23d
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
European Medicines Agency grants orphan medicinal product designation for Neurizon’s lead drug candidate NUZ-001 to treat ALS Neurizon also reports positive interim eight-month update on its ...